Mostly Markets
Subscribe
Markets
S&P 500 ▼ 1.82%Nasdaq ▼ 2.86%Dow ▼ 1.09%Russell 2000 ▼ 1.66%10-year 4.93%Oil ▲ 0.93%Gold ▼ 3.63%Bitcoin ▲ 1.13%
Newest story
Stocks/Health Care/Biotechnology

ModernaMRNA

Biotechnology · Cambridge, Massachusetts · In the S&P 500
No profits yet
$221.72−0.47%After hours: $221.50 (−0.10%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 797.7% over 1 year
Moderna over 1 yearDaily close, $, to 30 Oct 2026
$100$200Nov2026MarMayJulSep$221.72$100$200NovMarJul$221.72
Source: Nasdaq daily closes
Market value$88.52B
Price to earnings–
Forward P/E–
Dividend yield–
Year to date+651.8%
One year+797.7%
Next earningsFri 6 Nov, before the open
SectorHealth Care
52-week range (closes)
$22.36$245.81

The latest on Moderna

Our stories first, then the headlines that could move it, newest first.

NewBig movers

Five Stocks That Made News This Week: Zscaler, Hasbro, Lam Research, Meta and Moderna

NewBig movers

Stocks Making the Biggest Moves Yesterday: Moderna, Lam Research, Spotify, Meta and P&G

NewChart

Three of the S&P 500's Five Best Stocks This Year Make AI Hardware

NewWhy it moved

Why Moderna (MRNA) Stock Is Sinking Today

Quality and valuation

How Moderna compares with other health care stocks. A description, not a recommendation.

Moderna and 7 biotechnology peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: weaker than mostValuation: no profits to value

A weaker business than most health care companies, with no profits yet to value.

Moderna has no positive earnings to put a price-to-earnings multiple on. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: −27.6% vs +7.8%
  • Keeps less of each sale (gross margin): 23.4% vs 65.3%
  • Less profitable (operating margin): −149.0% vs 13.3%
  • Turns less of its sales into cash: −55.8% vs 15.9%

Financials

From Moderna's SEC filings, through the quarter ending 30 Jun 2026. Hover or tap a bar for its value.

Revenue grew 2.1% from a year earlierQuarterly revenue, $bn, latest Q2 ’26
$0.0bn$0.5bn$1.0bn$1.5bnQ3 ’24Q1 ’25Q3 ’25$0.1bnQ2 ’26$0bn$1bnQ3 ’24Q1 ’25Q3 ’25$0.1bnQ2 ’26
Source: SEC filings
Growth slowed to +2.1% last quarterRevenue growth, year on year, %
0%100%200%Q3 ’24Q1 ’25Q3 ’252.1%Q2 ’260%200%Q3 ’24Q1 ’25Q3 ’252.1%Q2 ’26
Source: SEC filings
Operating margin was -562.1% last quarterOperating income as a share of revenue, %
−750%−500%−250%0%Q3 ’24Q1 ’25Q3 ’25−562.1%Q2 ’26−500%0%Q3 ’24Q1 ’25Q3 ’25−562.1%Q2 ’26
Source: SEC filings
Free cash flow was −$1.2 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $bn
$-1bn$0bnQ3 ’24Q1 ’25Q3 ’25−$0.6bnQ2 ’26$-1bn$0bnQ3 ’24Q1 ’25Q3 ’25−$0.6bnQ2 ’26
Source: SEC filings
Last 12 monthsMRNASector median
Revenue growth−27.6%+7.8%
Gross margin23.4%65.3%
Operating margin−149.0%13.3%
Free cash flow margin−55.8%15.9%

Similar companies

Biotechnology, by market value.

CompanyPriceTodayYTDValue
ABBVAbbVie$294.89+1.41%+29.1%$521B
AMGNAmgen$466.01+1.15%+42.4%$252B
GILDGilead Sciences$170.68+3.06%+39.1%$212B
VRTXVertex Pharmaceuticals$558.88+3.50%+23.3%$142B
REGNRegeneron Pharmaceuticals$927.89+13.33%+20.2%$95.53B
BIIBBiogen$253.62+1.59%+44.1%$37.49B
INCYIncyte$120.39+3.07%+21.9%$24.40B